MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and G

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. RKLB
9. SPCX
10. NKE

Go back to MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and G
(NASDAQ: MTVA) Delayed: 1.43 -0.1 (6.54%)
Previous Close $1.53    52 Week High $ 
Open $1.50    52 Week Low $ 
Day High $1.54    P/E N/A 
Day Low $1.41    EPS $ 
Volume 97,764